Immune reconstitution in advanced ovarian cancer patients undergoing first line chemotherapy
10.3321/j.issn:1007-8738.2009.11.018
- VernacularTitle:晚期卵巢癌患者一线化疗后机体免疫重建的动态研究
- Author:
Qinmei FENG
;
Wen DI
;
Xia WU
- Publication Type:Journal Article
- Keywords:
paclitaxel;
carboplatin;
ovarian cancer;
chemotherapy;
immune reconstitution
- From:
Journal of Cellular and Molecular Immunology
2009;25(11):1023-10,251,028
- CountryChina
- Language:Chinese
-
Abstract:
AIM: We investigated the numbers and proportions of lymphocyte subsets in advanced ovarian cancer patients undergoing chemotherapy, so as to identify whether there is immune reconstitution after chemotherapy, and seek rational chemo-immunotherapy strategies in ovarian cancer treatment. METHODS: Blood samples from each ovarian cancer patient were obtained before (S_0) and at day 5-7 (S_1), day 12-14 (S_2) and day 25-28 (S_3) after chemotherapy in 13 patients. Flow cytometry technique was employed to analyse the numbers, proportions of CD3~+, CD4~+, CD8~+, CD4~+CD25~+ Treg and memory-like phenotype lymphocyte subsets. RESULTS: Lymphopenia was observed at S1 after chemotherapy, but lymphocytes were found gradually recovered after S1. The numbers of CD3~+, CD4~+, CD8~+T cells and CD4~+CD25~+ Treg cells reduced to the lowest on S_1. The proportions of CD8~+ T cells and CD4~+CD25~+ Treg cells reduced to the lowest on S_1 and S_2 respectively. The proportions of CD45RO~+ memory T cells increased significantly on S2 while the proportion of CD8~+CD45RA~+ T cells decreased remarkably on S_2. CONCLUSION: Paclitaxel and carboplatin induce lymphopenia at day 5-7 after chemotherapy, then comes the temporary immune reconstitution. It probably turns out that the window period during immune reconstitution offers a best opportunity for cancer immunotherapy.
